title: Sonosensitive dioleoylphosphatidylethanolamine-containing liposomes with prolonged blood circulation time of doxorubicin.
abstract: Ultrasound sensitive (sonosensitive) liposomes represent a drug delivery system designed for releasing a drug load upon exposure to ultrasound (US). Inclusion of dioleoylphosphatidylethanolamine (DOPE) in liposome membranes was previously shown to induce sonosensitivity. Long blood circulation time of the liposomal drug is required for high tumour uptake and efficient US-mediated drug delivery. In this study, blood pharmacokinetics of DOPE-based liposomal doxorubicin (DXR) were evaluated in non-tumoured mice. A markedly faster blood clearance of DXR was observed for DOPE-rich liposomes compared to Caelyx® (standard liposomal DXR). Subsequently, liposome membrane composition was altered to improve drug retention in the bloodstream, whilst maintaining sonosensitivity. Formulations with reduced blood clearance of DXR were obtained by reducing the content of DOPE from 62 to 32 or 25 mol%. These formulations showed long blood circulation time, as approximately 20% of the administered DXR dose was present in the bloodstream 24 h after intravenous injection. The reduction in liposomal DOPE content did not significantly reduce US-mediated DXR release in vitro, indicating that DOPE is a potent modulator of sonosensitivity. The novel liposome formulations, containing moderate amounts of DOPE, displayed similar blood pharmacokinetic profiles as standard liposomal DXR, but a markedly improved sonosensitivity.
authors.affiliation: Epitarget AS, Oslo, Norway.
authors.forename: Tove J
authors.initials: TJ
authors.lastname: Evjen
authors.forename: Eirik
authors.initials: E
authors.lastname: Hagtvet
authors.forename: Esben A
authors.initials: EA
authors.lastname: Nilssen
authors.forename: Martin
authors.initials: M
authors.lastname: Brandl
authors.forename: Sigrid L
authors.initials: SL
authors.lastname: Fossheim
mesh_terms: D000818:Animals; D001776:Blood Circulation Time; D002784:Cholesterol / Q000737:chemistry; D004317:Doxorubicin / Q000008:administration & dosage / Q000097:blood* / Q000493:pharmacokinetics*; D016503:Drug Delivery Systems / Q000379:methods; D008055:Lipids / Q000737:chemistry; D008081:Liposomes / Q000008:administration & dosage / Q000097:blood / Q000737:chemistry*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D010714:Phosphatidylethanolamines / Q000008:administration & dosage / Q000097:blood / Q000737:chemistry / Q000493:pharmacokinetics*; D011092:Polyethylene Glycols / Q000737:chemistry; D014465:Ultrasonics / Q000379:methods
chemical_list: C519184:1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000); D008055:Lipids; D008081:Liposomes; D010714:Phosphatidylethanolamines; C094877:dioleoyl phosphatidylethanolamine; D011092:Polyethylene Glycols; D004317:Doxorubicin; D002784:Cholesterol